Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Barclays PLC (BCS) Investors

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Barclays PLC (“Barclays” or the “Company”) (NYSE: BCS) American Depositary Receipts (“ADRs”) between February 18, 2021 to March 25, 2022, inclusive (the “Class Period”). Barclays investors have until November 22, 2022 to file a lead plaintiff motion.

If you suffered a loss on your Barclays investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/barclays-plc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

On March 28, 2022, Barclays disclosed that its subsidiary, Barclays Bank PLC (“BBPLC”) had issued approximately $15.2 billion in unregistered securities under an August 2019 shelf registration, and that it would commence a rescission offer for those unregistered securities, expecting the losses to be approximately £450 million.

On this news, Barclays’ stock fell $0.96, or 10.6%, to close at $8.09 per ADR on March 28, 2022, thereby injuring investors.

Then, on July 28, 2022, Barclays issued interim financial results, announcing that BBPLC had also overissued unregistered securities under a second shelf registration statement. The Company disclosed that it had provisioned approximately $1.9 billion “related to the overissuance of structured notes” and approximately $201 million “related to liabilities that could be incurred arising out of ongoing discussion in respect of a potential SEC resolution.”

On this news, Barclays’ stock fell $0.41, or 5.2%, to close at $7.48 per ADR on July 28, 2022, thereby injuring investors further.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Barclays had a material weakness in its internal control environment due to the fact that the over-issuance had occurred and was not immediately identified; (2) BBPLC had and was selling unregistered securities in excess of the amounts registered by the August 2019 Shelf Registration Statement, (3) BBPLC was required to conduct a recission offer for those unregistered securities, and (4) BBPLC was violating U.S. securities laws and/or SEC regulations, subjecting Barclays to legal liability; and (5) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired Barclays ADRs during the Class Period, you may move the Court no later than November 22, 2022 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220927005239/en/